About Veana Therapeutics
Veana Therapeutics is a company based in Portland (United States) founded in 2012.. Veana Therapeutics has raised $1.37 million across 4 funding rounds from investors including HHS. Veana Therapeutics offers products and services including Mitochondria Inhibition Technology. Veana Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Portland, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Veana Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$1.37 M (USD)
in 4 rounds
-
Latest Funding Round
$394.68 K (USD), Grant
Aug 01, 2021
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Veana Therapeutics
Veana Therapeutics offers a comprehensive portfolio of products and services, including Mitochondria Inhibition Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Oral medicines that target and destroy cancer cell mitochondria to induce immune responses.
Unlock access to complete
Unlock access to complete
Funding Insights of Veana Therapeutics
Veana Therapeutics has successfully raised a total of $1.37M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $394.68 thousand completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Grant — $394,676
-
First Round
First Round
(29 May 2018)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2021 | Amount | Grant - Veana Therapeutics | Valuation |
investors |
|
| Nov, 2020 | Amount | Seed - Veana Therapeutics | Valuation |
investors |
|
| Sep, 2018 | Amount | Grant - Veana Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Veana Therapeutics
Veana Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Veana Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Veana Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Veana Therapeutics Comparisons
Competitors of Veana Therapeutics
Veana Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Veana Therapeutics
Frequently Asked Questions about Veana Therapeutics
When was Veana Therapeutics founded?
Veana Therapeutics was founded in 2012 and raised its 1st funding round 6 years after it was founded.
Where is Veana Therapeutics located?
Veana Therapeutics is headquartered in Portland, United States. It is registered at Portland, Oregon, United States.
Is Veana Therapeutics a funded company?
Veana Therapeutics is a funded company, having raised a total of $1.37M across 4 funding rounds to date. The company's 1st funding round was a Grant of $350.13K, raised on May 29, 2018.
What does Veana Therapeutics do?
Veana Therapeutics was founded in 2012 in Portland, United States, and operates in the biotechnology sector focused on oncology. Alpha-TEA compounds, derived from vitamin E analogs, are advanced as oral agents that target tumor cells while activating immune responses. The lead candidate, Vimo 101 (a TEA-Lys formulation), is currently in Phase 1 trials for indications including melanoma, esophageal cancer, renal cell carcinoma, and prostate cancer, among others.
Who are the top competitors of Veana Therapeutics?
Veana Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
What products or services does Veana Therapeutics offer?
Veana Therapeutics offers Mitochondria Inhibition Technology.
Who are Veana Therapeutics's investors?
Veana Therapeutics has 1 investor. Key investors include HHS.